Cardinal Health Inc
Health Care
Cardinal Health Inc (CAH) Stock News
The latest CAH headlines and market coverage — 2 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
Crinetics Pharmaceuticals announced positive Phase 2 trial results for atumelnant, an oral ACTH receptor antagonist for treating congenital adrenal hyperplasia (CAH). The drug demonstrated sustained androgen reductions while enabling patients to lower glucocorticoid supplementation to physiologically normal levels. Additional Phase 1b/2a data in ACTH-dependent Cushing's syndrome showed rapid cortisol reduction. The company is advancing atumelnant into late-phase clinical development with Phase 3 trials already underway.
- GlobeNewswire Inc.·
CAHI Honours The Honourable Don Boudria for Leadership in Animal Health
The Canadian Animal Health Institute (CAHI) announced its 2026 Annual Awards, presenting the Industry Leadership Award to former Cabinet Minister Don Boudria for his contributions to advancing animal health policy, and the Chair's Award to Dr. Arman Panah from Virbac for his leadership in regulatory modernization and industry collaboration.